Compare MYO & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYO | NSRX |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8M | 38.9M |
| IPO Year | 2017 | N/A |
| Metric | MYO | NSRX |
|---|---|---|
| Price | $1.07 | $3.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $7.67 | ★ $19.67 |
| AVG Volume (30 Days) | ★ 317.1K | 10.0K |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000,000.00 | N/A |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $13.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40814.79 | N/A |
| 52 Week Low | $0.61 | $1.98 |
| 52 Week High | $2.02 | $9.99 |
| Indicator | MYO | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 52.32 |
| Support Level | $0.89 | $2.83 |
| Resistance Level | $1.17 | $3.60 |
| Average True Range (ATR) | 0.09 | 0.18 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 73.07 | 78.93 |
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.